Look back at pharma news in the week to July 24, 2020

26 July 2020

Last week’s notable news continued with a strong focus on the novel coronavirus, with UK respiratory drug developer Synairgen presenting new data on its SNG001 inhaled interferon candidate for hospitalized COVID-19 patients, sending the firm’s shares into the stratosphere. AstraZeneca and Oxford University released encouraging Phase I/II results for their COVID-19 vaccine candidate ChAdOx1/AZD1222. Also, BioNTech and Pfizer released positive COVID-19 vaccine data. Additionally, US biotech Incyte reported strong Phase III results for its graft-versus-host (GVID) drug Jakafi.

Synairgen joins the 2020 coronavirus winners club

With investors and governments itching to analyze the first clinical data from AstraZeneca/Oxford University’s COVID-19 vaccine last Monday, it was in fact a different UK company – the tiny biotech Synairgen – that seized most of the morning’s attention, noted Jacob Plieth writing on Evaluate Vantage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK